Cardlytics Inc (NASDAQ:CDLX) Expected to Announce Earnings of -$0.15 Per Share

Equities analysts predict that Cardlytics Inc (NASDAQ:CDLX) will announce ($0.15) earnings per share for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Cardlytics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.24). Cardlytics also reported earnings of ($0.15) per share in the same quarter last year. The firm is expected to report its next earnings results after the market closes on Tuesday, November 12th.

According to Zacks, analysts expect that Cardlytics will report full-year earnings of ($0.62) per share for the current year, with EPS estimates ranging from ($0.80) to ($0.49). For the next year, analysts anticipate that the business will report earnings of ($0.14) per share, with EPS estimates ranging from ($0.39) to $0.25. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Cardlytics.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.23. The firm had revenue of $48.73 million during the quarter, compared to analysts’ expectations of $43.77 million. Cardlytics had a negative net margin of 19.60% and a negative return on equity of 66.01%. The business’s revenue was up 37.0% on a year-over-year basis. During the same period last year, the company earned ($0.21) earnings per share.

Several analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday, October 31st. SunTrust Banks boosted their price target on shares of Cardlytics from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Bank of America reissued a “buy” rating and issued a $32.00 price target (up previously from $22.00) on shares of Cardlytics in a research report on Wednesday, July 24th. ValuEngine lowered shares of Cardlytics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. set a $43.00 price target on shares of Cardlytics and gave the company a “buy” rating in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. Cardlytics presently has an average rating of “Buy” and a consensus target price of $34.86.

Shares of NASDAQ CDLX traded up $0.01 during mid-day trading on Friday, reaching $40.01. 308,900 shares of the company’s stock traded hands, compared to its average volume of 312,529. The stock has a market cap of $928.40 million, a P/E ratio of -18.70 and a beta of 1.56. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.01 and a quick ratio of 2.01. Cardlytics has a 1-year low of $9.80 and a 1-year high of $42.19. The business has a 50-day simple moving average of $36.89 and a 200 day simple moving average of $29.43.

In related news, Director Tony Weisman sold 33,484 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $31.36, for a total transaction of $1,050,058.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Aimia Inc. sold 1,500,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $29.95, for a total transaction of $44,925,000.00. The disclosure for this sale can be found here. In the last three months, insiders bought 316,475 shares of company stock worth $11,914,849 and sold 2,649,922 shares worth $83,318,325. Insiders own 21.90% of the company’s stock.

Large investors have recently modified their holdings of the stock. Bank of Montreal Can grew its stake in Cardlytics by 16,371.4% during the second quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock valued at $30,000 after acquiring an additional 1,146 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new position in Cardlytics during the second quarter valued at approximately $60,000. Rockefeller Capital Management L.P. purchased a new position in Cardlytics during the second quarter valued at approximately $85,000. Tower Research Capital LLC TRC grew its stake in Cardlytics by 35.0% during the third quarter. Tower Research Capital LLC TRC now owns 4,079 shares of the company’s stock valued at $137,000 after acquiring an additional 1,057 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in Cardlytics during the second quarter valued at approximately $161,000. 79.61% of the stock is owned by institutional investors.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

See Also: Why Net Income is Important to Investors

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.